David G. Daniel

5.3k total citations · 1 hit paper
91 papers, 3.9k citations indexed

About

David G. Daniel is a scholar working on Psychiatry and Mental health, Clinical Psychology and Experimental and Cognitive Psychology. According to data from OpenAlex, David G. Daniel has authored 91 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Psychiatry and Mental health, 17 papers in Clinical Psychology and 13 papers in Experimental and Cognitive Psychology. Recurrent topics in David G. Daniel's work include Schizophrenia research and treatment (47 papers), Bipolar Disorder and Treatment (14 papers) and Mental Health Research Topics (12 papers). David G. Daniel is often cited by papers focused on Schizophrenia research and treatment (47 papers), Bipolar Disorder and Treatment (14 papers) and Mental Health Research Topics (12 papers). David G. Daniel collaborates with scholars based in United States, United Kingdom and Switzerland. David G. Daniel's co-authors include Stephen R. Marder, Linh P. Nguyen, Gregory P. Strauss, Bernard A. Fischer, Brian Kirkpatrick, Angel Cienfuegos, Daniel R. Weinberger, Daniel E. Casey, Patricia Wozniak and Felicia Trachtenberg and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Stroke.

In The Last Decade

David G. Daniel

86 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Brief Negative Symptom Scale: Psychometric Properties

2010 640 citations Brian Kirkpatrick, Gregory P. Strauss et al. Schizophrenia Bulletin profile →

Peers

Countries citing papers authored by David G. Daniel

Since Specialization

Citations

This map shows the geographic impact of David G. Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Daniel more than expected).

Fields of papers citing papers by David G. Daniel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Daniel. The network helps show where David G. Daniel may publish in the future.

Co-authorship network of co-authors of David G. Daniel

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Daniel. A scholar is included among the top collaborators of David G. Daniel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Daniel. David G. Daniel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EDG-7500, A First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, And Pharmacokinetics In Healthy Adults 2025 ·Journal of Cardiac Failure ·Christopher Dufton, Marc Evanchik, David G. Daniel, Jeffrey A. Silverman, (unknown), (unknown), James E. MacDougall, (unknown), (unknown), Marc J. Semigran	3
2	Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms 2024 ·Schizophrenia Bulletin Open ·David G. Daniel, Alex S. Cohen, Philip D. Harvey, Dawn I. Velligan, William Z. Potter, William P. Horan, Raeanne C. Moore, Stephen R. Marder	2
3	Replicating and Extending the Reliability, Criterion Validity, and Treatment Sensitivity of the PANSS10 and PANSS20 for Pediatric Trials 2024 ·PubMed ·Eric A. Youngstrom, (unknown), David G. Daniel, Joan Busner, Robert L. Findling	2
4	Remote Assessment of Negative Symptoms of Schizophrenia 2023 ·Schizophrenia Bulletin Open ·David G. Daniel, Alex S. Cohen, Dawn I. Velligan, P.D. Harvey, Larry Alphs, Michael Davidson, William Z. Potter, (unknown), Nina R. Schooler, (unknown), Raeanne C. Moore, (unknown), Stephen R. Marder	5
5	Relationships among hospital acute ischemic stroke volumes, hospital characteristics, and outcomes in the US 2023 ·Journal of Stroke and Cerebrovascular Diseases ·(unknown), David G. Daniel, (unknown), Mandip S. Dhamoon	2
6	Provider care segregation and hospital-region racial disparities for carotid interventions in the USA 2023 ·Journal of NeuroInterventional Surgery ·David G. Daniel, (unknown), Mandip S. Dhamoon	0
7	An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric Trials 2022 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Robert L. Findling, Eric A. Youngstrom, Jon McClellan, Jean A. Frazier, Linmarie Sikich, David G. Daniel, Joan Busner	4
8	Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data 2018 ·Schizophrenia Research ·Willie Earley, Hua Guo, David G. Daniel, Henry A. Nasrallah, Suresh Durgam, Yan Zhong, Mehul Patel, Ágota Barabássy, B. Szatmári, György Németh	53
9	Issues in Selection of Instruments to Measure Negative Symptoms 2013 ·Schizophrenia Research ·David G. Daniel	54
10	Training for Assessment of Negative Symptoms of Schizophrenia across Languages and Cultures: Comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom Factor 2011 ·Clinical Schizophrenia & Related Psychoses ·David G. Daniel, Larry Alphs, Pilar Cazorla, John J. Bartko, John Panagides	19
11	The Brief Negative Symptom Scale: Psychometric Properties breakdown → 2010 ·Schizophrenia Bulletin ·Brian Kirkpatrick, Gregory P. Strauss, Linh P. Nguyen, Bernard A. Fischer, David G. Daniel, Angel Cienfuegos, Stephen R. Marder	640
12	Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia 2008 ·Neuropsychopharmacology ·Daniel E. Casey, David G. Daniel, Carol A. Tamminga, John M. Kane, Tram Tran-Johnson, Patricia Wozniak, Walid Abi‐Saab, Jeff Baker, Laura Redden, Nicholas J. Greco, Mario Saltarelli	41
13	Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations 2007 ·Journal of Psychiatric Practice ·David G. Daniel, Glenn W. Currier, Dan Zimbroff, Michael H. Allen, Dan A. Oren, George Manos, Robert D. McQuade, (unknown), David Crandall	20
14	Standard therapies for acute agitation 2004 ·Journal of Emergency Medicine ·Glenn W. Currier, Michael H. Allen, E. Bradshaw Bunney, David G. Daniel, Andrew Francis, Andy Jagoda, Dan Zimbroff	10
15	Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia 2003 ·Neuropsychopharmacology ·Daniel E. Casey, David G. Daniel, Adel Wassef, Katherine Tracy, Patricia Wozniak, Kenneth W. Sommerville	165
16	Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial 2001 ·Psychopharmacology ·David G. Daniel, Steven G. Potkin, Karen R. Reeves, R.H. Swift, Edmund P. Harrigan	126
17	Olanzapine Versus Placebo in the Treatment of Acute Mania 1999 ·American Journal of Psychiatry ·Mauricio Tohen, T.M. Sanger, Susan L. McElroy, Gary D. Tollefson, K. N. Roy Chengappa, David G. Daniel, Frederick Petty, Franca Centorrino, (unknown), Starr L. Grundy, (unknown), T. Jacobs, S.R. David, V. Toma, (unknown)	443
18	Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF‐α, and IL‐1β 1993 ·Journal of Cellular Physiology ·Seitaro Fujishima, Andrew R. Hoffman, Thanh Vu, (unknown), (unknown), David G. Daniel, Youngmee Kim, Ellen F. Wallace, James W. Larrick, Thomas A. Raffin	134
19	Regional cerebral blood flow during the wisconsin card sorting test in normal subjects studied by xenon-133 dynamic SPECT: Comparison of absolute values, percent distribution values and covariance analysis 1993 ·Psychiatry Research Neuroimaging ·Stefano Marenco, Richard Coppola, David G. Daniel, (unknown), Daniel R. Weinberger	73
20	Sex roles and regional cerebral blood flow 1989 ·Psychiatry Research ·David G. Daniel, Roy J. Mathew, William H. Wilson	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact